Review Article
Distinguishing Depressive Symptoms From Similar Cancer-Related Somatic Symptoms: Implications for Assessment and Management of Major Depression after Breast Cancer
Abstract
Prevalence rates of major depressive disorder (MDD) following breast cancer diagnosis are estimated to be ~5% to >20%, and these rates range from slightly below to somewhat above the expected prevalence rate for MDD in the general population of women in the United States. Women with a history of MDD are at increased risk for recurrence of MDD after breast cancer and need to be monitored closely. To properly diagnose and treat MDD, healthcare providers must be able to recognize depressive symptoms and distinguish them from similar somatic symptoms that are associated with breast cancer and breast cancer treatment. The National Comprehensive Cancer Network and the American Society of Clinical Oncology have published guidelines for the screening, assessment, and care of adult cancer patients with depressive symptoms. Use of a standardized and validated screening measure may help healthcare providers identify patients in need of further assessment or treatment. Evidence-based nonpharmacological interventions such as cognitive behavioral therapy and antidepressant medications are recommended treatment options.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC:American Psychiatric Association, 2013.
2. Alici Y, Bower JE, Breitbart WS. Fatigue. In: Holland JC, Breitbart WS, Butow PN, et al. , eds. Psycho-Oncology. 3rd ed. New York: Oxford University Press, 2015:209-219.
3. Fearon KC, Voss AC, Hustead DS, et al. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006;83:1345-1350.
4. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001;19:895-908.
5. Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005;59:60-70.
6. Centeno C, Sanz Á, Bruera E. Delirium in advanced cancer patients. Palliat Med 2004;18:184-194.
7. Fann JR, Thomas-Rich AM, Katon WJ, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 2008;30:112-126.
8. Gandubert C, Carrière I, Escot C, et al. Onset and relapse of psychiatric disorders following early breast cancer: a case-control study. Psychooncology 2009;18:1029-1037.
9. Hill J, Holcombe C, Clark L, et al. Predictors of onset of depression and anxiety in the year after diagnosis of breast cancer. Psychol Med 2011;41:1429-1436.
10. Qiu J, Yang M, Chen W, et al. Prevalence and correlates of major depressive disorder in breast cancer survivors in Shanghai, China. Psychooncology 2012;21:1331-1337.
11. Stanton AL, Wiley JF, Krull JL, et al. Depressive episodes, symptoms, and trajectories in women recently diagnosed with breast cancer. Breast Cancer Res Treat 2015;154:105-115.
12. National Institute of Mental Health. Major depression among adults. https://www.nimh.nih.gov/health/statistics/prevalence/major-depression-among-adults.shtml. Accessed May 21, 2017.
13. Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: Study of Women’ Health Across the Nation (SWAN). Psychol Med 2011;41:1879-1888.
14. Colvin A, Richardson GA, Cyranowski JM, et al. Does family history of depression predict major depression in midlife women? Study of Women’s Health Across the Nation Mental Health Study (SWAN MHS). Arch Womens Ment Health 2014;17:269-278.
15. Coyne JC, Palmer SC, Shapiro PJ, et al. Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast cancer waiting room sample. Gen Hosp Psychiatry 2004;26:121-128.
16. Brandão T, Schulz MS, Matos PM. Psychological adjustment after breast cancer: a systematic review of longitudinal studies. Psychooncology 2017;26:917-926.
17. Lee MK, Park S, Lee ES, et al. Social support and depressive mood 1 year after diagnosis of breast cancer compared with the general female population: a prospective cohort study. Support Care Cancer 2011;19:1379-1392.
18. Adler NE, Page AE. Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs. Washington, DC: National Academies Press, 2008.
19. National Comprehensive Cancer Network. Distress management, version 2. 2016. https://www.nccn.org/professionals/physician_gls/pdf/distress.pdf. Published July 25, 2016. Accessed November 23, 2016.
20. Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 2014;32:1605-1619.
21. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 2016;34:611-635.
22. Roth AJ, Kornblith AB, Batel-Copel L, et al. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer 1998;82:1904-1908.
23. Mitchell AJ. Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol 2007;25:4670-4681.
24. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-613.
25. Gilbody S, Richards D, Brealey S, et al. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 2007;22:1596-1602.
26. Thekkumpurath P, Walker J, Butcher I, et al. Screening for major depression in cancer outpatients: the diagnostic accuracy of the 9-item patient health questionnaire. Cancer 2011;117:218-227.
27. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
28. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX:The Psychological Corporation , 1996;:82.
29. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
30. HealthMeasures. PROMIS: Patient-Reported Outcomes Measurement Information System. http://www.healthmeasures.net/explore-measurement-systems/promis. Accessed November 23, 2016.
31. von Ammon Cavanaugh S. Depression in the medically ill. Critical issues in diagnostic assessment. Psychosomatics 1995;36:48-59.
32. Endicott J. Measurement of depression in patients with cancer. Cancer 1984;53(10 Suppl):2243-2249.
33. Fitzgerald P, Miller K, Li M, et al. Depressive disorders. In: Holland JC, Breitbart WS, Jacobsen PB, eds. Psycho-Oncology. 3rd ed. New York :Oxford University Press, 2015:281-288.
34. Koenig HG, George LK, Peterson BL, et al. Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry 1997;154:1376-1383.
35. Akechi T, Ietsugu T, Sukigara M, et al. Symptom indicator of severity of depression in cancer patients: a comparison of the DSM-IV criteria with alternative diagnostic criteria. Gen Hosp Psychiatry 2009;31:225-232.
36. Faller H, Schuler M, Richard M, et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol 2013;31:782-793.
37. Hart SL, Hoyt MA, Diefenbach M, et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst 2012;104:990-1004.
38. Qiu J, Chen W, Gao X, et al. A randomized controlled trial of group cognitive behavioral therapy for Chinese breast cancer patients with major depression. J Psychosom Obstet Gynaecol 2013;34:60-67.
39. Nezu AM, Nezu CM, Perri MG. Problem-Solving Therapy for Depression: Theory, Research, and Clinical Guidelines. New York: John Wiley & Sons, 1989.
40. Ell K, Xie B, Kapetanovic S, et al. One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. Psychiatr Serv 2011;62:162-170.
41. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001;345:1719-1726.
42. Breitbart W, Poppito S, Rosenfeld B, et al. Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer. J Clin Oncol 2012;30:1304-1309.
43. Chochinov HM, Kristjanson LJ, Breitbart W, et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol 2011;12:753-762.
44. Ostuzzi G, Matcham F, Dauchy S, et al. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev 2015;CD011006.
45. Moraska AR, Jones JM, Sideras K, et al. Management of hot flashes in breast cancer patients. Eur J Clin Med Oncol 2012;4:1-9.
46. Fallon MT. Neuropathic pain in cancer. Br J Anaesth 2013;111:105-111.
47. Cankurtaran ES, Ozalp E, Soygur H, et al. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer 2008;16:1291-1298.
48. Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 2001;9:469-470.
49. Kerr CW, Drake J, Milch RA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 2012;43:68-77.
50. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70:1688-1697.
51. Haque R, Shi J, Schottinger JE, et al. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst 2016;108.
52. American Psychiatric Association. Treating major depressive disorder: a quick reference guide. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd-guide.pdf. Published October 2010. Accessed November 29, 2016.
